HER2 Amplification Shows Prognostic Capabilities in mCRC
August 28th 2023Although HER2 amplification showed prognostic capabilities in patients with RAS wild-type metastatic colorectal cancer (mCRC), it was not predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.
Read More
Time to Treatment Initiation Affected by Demographics, Socioeconomics in CRC, NSCLC
August 18th 2023Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of time to treatment initiation.
Read More
Delays Between CRC Presentation, Treatment Not Associated With Poor Survival in Young Adults
August 3rd 2023Adults younger than 50 years with colorectal cancer (CRC) who experience postpresentation delays in treatment did not appear to have worse outcomes, according to a study in Ontario, Canada.
Read More
A “Sludge Audit” for Health System Colorectal Cancer Screening Services
A systematic, mixed methods “sludge audit” identified novel health system delivery targets for improving colorectal cancer screening services.
Read More
Takeda Stakes $1.13 Billion on Rights to Fruquintinib for Advanced Refractory Colorectal Cancer
January 23rd 2023Under the agreement, Takeda will pay Hutchmed $400 million up front and up to $730 million in additional potential payments relating to regulatory, development, and commercial sales milestones, as well as royalties on worldwide net sales, with the exception of mainland China, Hong Kong, and Macau.
Read More
Tucatinib Plus Trastuzumab Approved for RAS Wild-type, HER2+ Unresectable or Metastatic CRC
January 19th 2023The combination of tucatinib and trastuzumab received accelerated approval from the FDA to treat adults with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer (mCRC) that advances after treatment with specific types of chemotherapy.
Read More
Medicaid Expansion May Result in Earlier Colon Cancer Diagnosis, Study Says
December 13th 2020The authors wrote that in states that expanded Medicaid health insurance coverage in 2014, there was an increase of early-stage colon cancer diagnoses compared with states that did not implement expansion.
Read More
AI Helps Determine Which Patients Benefit Most From Colorectal Cancer Treatment
December 9th 2020Researchers found the application of FOLFOXai, an artificial intelligence (AI)–based predictor of response to FOLFOX chemotherapy in metastatic colorectal cancer (mCRC), may lead to improved treatment outcomes for some patients with mCRC and other cancers.
Read More
Impact of Travel Distance on Quality Outcomes in Colorectal Cancer
This study identified characteristics of patients with colorectal cancer who traveled farther for surgery and found that those who traveled tended to stay longer at the hospital.
Read More
Biomarker Use in Colorectal Cancer
December 18th 2019Despite a 20% drop in mortality since 2009, colorectal cancer accounted for 9.8% (881,000) of deaths worldwide in 2018 and represents 10.2% of all cancer cases worldwide. It is No. 3 on the list of most prevalent cancers worldwide—1.8 million new cases in 2018—behind only lung cancer and breast cancer.
Read More
NGS Identifies Survival, Treatment Outcomes for Patients With CRC Genetic Mutations
April 7th 2019Genetic alternations in colorectal cancer (CRC) are linked to different survival and treatment outcomes, according to a study that used next-generation sequencing (NGS) of tumor DNA. The study was published in Journal of Clinical Oncology.
Read More